

1/28 54

FIGURE 1A

1 CGGATGCTGC TGCTACTGTC ACTTCTGCCG CTGCCGCTGT TGTTACAGAT
51 TTTGCTTTTG CTCCTTCTAC CGCATGACAA TTGTTTTCTT CGCCTAAGCA
101 GATACCAGCC TCAGATGCTC AAGGTGAGAG TCTTGCCTTT CGCTCTGGGC
151 TATTGGTTCA CTTAATCCGG TCAATTTGTT CGCTGCTCGT GGTTGTCTTT
201 CTCCCCGCCC TCCTTCCCCC TGTTTTGTTT TGTTTCGCTT GCTTTCGGGG
251 GGACGCTCCT TCCCTCAGTC AGAAGAGCTG GAATTGCTTG AGAGGCGTAT
301 AAGGAATTAT AAAAGTGGCC AGGAAACACG AGCGCAGTGA CTGCAGAGCT
351 GCCCTTGGCT TCGGCAAGGC AGCGTGAGCG GCAGAGGGCT CGGGCAGGGG
401 GCGGGGGGTC TCCTTTTTC C GTGCGTTCC TCTTCTCCCA GTTCGGATGA
451 TGTTGCTGTT TCGGACCTCT CGCTGACTCC TGCCCTGTGA TTTTGTCTGA
501 GCGCTGTGAC TGTTACTCCG TCTCTTTCTG TCTGTGTTTC ACAGTAATGG
551 ACTGTGATAG AGTTAAGGCC TTTTGGAGGT GAGCTGTGTC ACAGCTGATG
601 CTTAAACATG TCTGAAGTAG GCACCGAGAC TTTCCCCAGC CCCTCGGCTC
651 AGCTGAGCCC TGATGCATCC CTGGCGGGC TCCCGGCTGA GGAGAACATG
701 CCGGGGCCCC ACAGAGAGGA CAGCAGGGTC CCAGGTGTGG CAGGCCTGGC
751 CTCGACCTGC TGCSTGTGCC TGGAAGCAGA GCGACTGAAG GGCTGCCTCA
801 ACTCTGAGAA GATCTGCATC GCCCCTATCC TGGCTTGCCT GCTCAGCCTC
851 TGCCTCTGCA TTGCTGGCCT CAAGTGGGTC TTTGTGGACA AGATTTTGA
901 GTATGACTCT CCTACACACC TTGACCCTGG GAGGATAGGA CAAGACCCAA
951 GGAGCACTGT GGATCCTACA GCTCTGTCTG CCTGGGTGCC TTCGGAGGTG
1001 TATGCCTCAC CCTTCCCCAT ACCTAGCCTT GAGAGCAAGG CTGAAGTGAC
1051 AGTGCAAAC TACAGCTCGC TCGTGCCCTC CAGGCCCTTC CTTCAGCCTT
1101 CTCTCTACAA CCGCATCCTA GATGTCGGGT TGTGGTCCTC TGCCACACCG
1151 TCACTGTCAC CATCCTCCCT GGAGCCTACC ACGGCATCTC AGGCACAAGC
1201 AACAGAAACC AATCTCCAAA CTGCTCCAAA ACTTTCCACT TCTACATCTA
1251 CAACTGGGAC AAGTCATCTC ACAAATGTG ACATAAAGCA GAAAGCCTTC
1301 TGTGTAAATG GGGGAGAGTG CTACATGGTT AAAGACCTCC CAAACCCTCC

09312595-051499

2/25 54

FIGURE 1B

1351 ACGATACCTA TGCAGGTGCC CAAATGAATT TACTGGTGAT CGCTGCCAAA
1401 ACTACGTAAT GGCAGCTTC TACAAGCATC TTGGGATTGA ATTTATGGAA
1451 GCTGAGGAAC TGTACCAGAA ACGGGTGCTG ACCATAACTG GCATTTGCAT
1501 TGCTCTTCTA GTAGTTGGCA TCATGTGTGT GGTGGCCTAC TGCAAAACCA
1551 AGAAGCAGAG GAAAAAGTTG CATGACCGCC TTCGGCAGAG CCTTCGCTCA
1601 GAGAGGAACA ACGTTATGAA CATGGCAAAT GGGCCACACC ACCCCAACCC
1651 ACCACCAGAC AATGTCCAGC TGGTGAATCA GTACGTTTCA AAAACATAA
1701 TCTCCAGTGA ACGTGTGCTT GAGCGAGAAA CCGAGACCTC GTTTTCCACA
1751 AGCCACTACA CCTCAACAAC TCATCACTCC ATGACAGTCA CCCAGACGCC
1801 TAGCCACAGC TGGAGTAATG GCCATACCGA AAGCATTCTC TCCGAAAGCC
1851 ACTCCGTGCT CGTCAGCTCC TCAGTGGAGA ATAGCAGGCA CACCAGCCCA
1901 ACAGGGCCAC GAGGCCGCCT CAATGGCATT GGTGGGCCAA GGAAGGCAA
1951 CAGCTTCCTC CGGCATGCAA GAGAGACCCC TGACTCCTAC CGAGACTCTC
2001 CTCACAGTGA AAGGTATGTC TCAGCTATGA CCACACCAGC TCGCATGTCA
2051 CCCGTTGATT TCCCACTCC AACTTCTCCC AAGTCCCCTC CATCTGAAAT
2101 GTCACCACCA GTTTCAGCT TGACCATCTC CATCCCTTCG GTGGCGGTGA
2151 GTCCCTTTAT GACGAGGAG AGACCGCTGC TGTGGTGAC CCCACCACGG
2201 CTGCGTGAGA AGTACGACAA CCACCTTCAG CAATTCAACT CCTTCCACAA
2251 CAATCCCACC CATGAGAGCA ACAGTCTGCC ACCCAGTCCT CTGAGGATAG
2301 TGGAGGATGA AGAGTATGAG ACCACGCAGG AGTACGAACC AGCACAGGAG
2351 CCTCCAAAGA AACTCACCAA CAGCCGGAGG GTGAAAAGAA CAAAGCCCAA
2401 TGGCCATATT TCCAGCAGGG TAGAAGTGGA CTCCGACACA AGCTCTCAGA
2451 GCACTAGCTC TGAGAGCGAA ACAGAAGATG AAAGAATAGG TGAGGATACA
2501 CCATTTCTTA GCATACAAAA TCCCATGGCA ACCAGTCTGG AGCCAGCCGC
2551 TGCATATCGG CTGGCTGAGA ACAGGACTAA CCCGGCAAAT CGCTTCTCCA
2601 CACCAGAAGA GTTGCAAGCA AGGTTGTCCA GTGTAATAGC TAACCAAGAC
2651 CCTATTGCTG TATAAGACAT AAACAAAACA CATAGATTCA CATGTAAAC

09312596:051499

3/25 54

FIGURE 1C

2701 TTTATTTTAT ATAATGAAGT ATTCCACCTT TAAATTAAAC AATTTATTTT
2751 ATTTTAGCAA TTCCGCTGAT AGAAAACAAG AGTGGAAAAA GAAACTTTTA
2801 TAAATTAAGT ATACGTATGT ACAAATGTGT TATGTGCCAT ATGTAGCAAT
2851 TTTTACAGT ATTTCCAAAA TGGGGAAAGA TATCAATGGT GCCTTTATGT
2901 TATGTTATGT TGAGAGCAAG TTTTGTACAG CTACAATGAT TGCTGTCCCG
2951 TAGTATTTTG CAAAACCTTC TAGCCCTCAG TTGTTCTGGC TTTTTTGTGC
3001 ATTGCATTAT AATGACTGGA TGTATGATTT GCAAGAATTG CAGAAGTCCC
3051 CATTTGCTTG TTGTGGAATC CCCAGATCAA AAAGCCCTGT TATGGCACTC
3101 ACACCCTATC CACTTCACCA GGAAAAAAAA AAAATCAAAA AAAAAAAAAA
3151 AAAAAAAGA AAAGAAAGAG AAAAAAGAAA AGAAAAAGAA AAAAAAGCT
3201 GAAAAAATAA AA

001250 15149

4/26 54

FIGURE 2

1 G C C C Y C H F C R C R C C Y R F C F C S F Y R M T I V F L A * A D T S L R C S R * E S C L S L W A
51 I G S L N P V N L F A A R G C L S P R P P S P C F V L F R L L S G G R S F P Q S E E L E L L E R R I
101 R N Y K S G Q E T R A Q * L Q S C P W L R Q G S V S G R G L G Q G A G G L L F P V R S S S P S S D D
151 V A V S D L S L T P A L * F L L S A V T V T P S L S V C V S Q * W T V I E L R P F G G E L C H S * C
201 L N M S E V G T E T F P S P S A Q L S P D A S L G G L P A E E N M P G P H R E D S R V P G V A G L A
251 S T C C V C L E A E R L K G C L N S E K I C I A P I L A C L L S L C L C I A G L K W V F V D K I F E
301 Y D S P T H L D P G R I G Q D P R S T V D P T A L S A W V P S E V Y A S P F P I P S L E S K A E V T
351 V Q T D S S L V P S R P F L Q P S L Y N R I L D V G L W S S A T P S L S P S S L E P T T A S Q A Q A
401 T E T N L Q T A P K L S T S T S T T G T S H L T K C D I K Q K A F C V N G G E C Y M V K D L P N P P
451 R Y L C R C P N E F T G D R C Q N Y V M A S F Y K H L G I E F M E A E E L Y Q K R V L T I T G I C I
501 A L L V V G I M C V V A Y C K T K K Q R K K L H D R L R Q S L R S E R N N V M N M A N G P H H P N P
551 P P D N V Q L V N Q Y V S K N I I S S E R V V E R E T E T S F S T S H Y T S T T H H S M T V T Q T P
601 S H S W S N G H T E S I L S E S H S V L V S S S V E N S R H T S P T G P R G R L N G I G G P R E G N
651 S F L R H A R E T P D S Y R D S P H S E R Y V S A M T T P A R M S P V D F H T P T S P K S P P S E M
701 S P P V S S L T I S I P S V A V S P F M D E E R P L L L V T P P R L R E K Y D N H L Q Q F N S F H N
751 N P T H E S N S L P P S P L R I V E D E E Y E T T Q E Y E P A Q E P P K K L T N S R R V K R T K P N
801 G H I S S R V E V D S D T S S Q S T S S E S E T E D E R I G E D T P F L S I Q N P M A T S L E P A A
851 A Y R L A E N R T N P A N R F S T P E E L Q A R L S S V I A N Q D P I A V * D I N K T H R F T C K T
901 L F Y I M K Y S T F K L N N L F Y F S N S A D R K Q E W K K K L L * I K Y T Y V Q M C Y V P Y V A I
951 F Y S I S K M G K D I N G A F M L C Y V E S K F C T A T M I A V P * Y F A K P S S P Q L F W L F C A
1001 L H Y N D W M Y D L Q E L Q K S P F A C C G I P R S K S P V M A L T P Y P L H Q E K K K I K K K K K
1051 K K R K E R E K R K E K E K S * K N K

00312596 051496

5/25 54

FIGURE 3

1 CGGCCTGTAA GATGCTGTAT CATTTGGTTG GGGGGGCCTC TGCGTGGTAA
51 TGGACCGTGA GAGCGGCCAG GCCTTCTTCT GGAGGTGAGC CGATGGAGAT
101 TTATTCCCCA GACATGTCTG AGGTCGCCGC CGAGAGGTCC TCCAGCCCCCT
151 CCACTCAGCT GAGTGCAGAC CCATCTCTTG ATGGGCTTCC GGCAGCAGAA
201 GACATGCCAG AGCCCCAGAC TGAAGATGGG AGAACCCCTG GACTCGTGGG
251 CCTGGCCGTG CCCTGCTGTG CGTGCCTAGA AGCTGAGCGC CTGAGAGGTT
301 GCCTCAACTC AGAGAAAATC TGCATTGTCC CCATCCTGGC TTGCCTGGTC
351 AGCCTCTGCC TCTGCATCGC CGGCCTCAAG TGGGTATTTG TGGACAAGAT
401 CTTTGAATAT GACTCTCCTA CTCACCTTGA CCCTGGGGGG TTAGGCCAGG
451 ACCCTATTAT TTCTCTGGAC GCAACTGCTG CCTCAGCTGT GTGGGTGTCTG
501 TCTGAGGCAT ACACTTCACC TGTCTCTAGG GCTCAATCTG AAAGTGAGGT
551 TCAAGTTACA GTGCAAGGTG ACAAGGCTGT TGTCTCCTTT GAACCATCAG
601 CGGCACCGAC ACCGAAGAAT CGTATTTTTG CCTTTTCTTT CTTGCCGTCC
651 ACTGCGCCAT CCTTCCCTTC ACCCACCCGG AACCCCTGAGG TGAGAACGCC
701 CAAGTCAGCA ACTCAGCCAC AAACAACAGA AACTAATCTC CAAACTGCTC
751 CTAAACTTTC TACATCTACA TCCACCACTG GGACAAGCCA TCTTGTAATA
801 TGTGCGGAGA AGSAGAAAAC TTTCTGTGTG AATGGAGGGG AGTGCTTCAT
851 GGTGAAAGAC CTTTCAAACC CCTCGAGATA CTTGTGCAAA GCGGAGGAG
901 CTGTACCAGA AGAGAGTGCT GACCATAACC GGCATCTGCA TCGCCCTCCT
951 TGTGGTCGGC ATCATGTGTG TGGTGGCCTA CTGCAAAACC AAGAAACAGC
1001 GGAAAAAGCT GCATGACCGT CTTCCGGCAGA GCCTTCGGTC TGAACGAAAC
1051 AATACGATGA ACATTGCCAA TGGGCCCTCAC CATCCTAACC CACCCCCCGA
1101 GAATGTCCAG CTGGTGAATC AATACGTATC TAAAAACGTC ATCTCCAGTG
1151 AGCATATTGT TGAGAGAGAA GCAGAGACAT CCTTTTCCAC CAGTCACTAT
1201 ACTTCCACAG CCCATCACTC CACTACTGTC ACCCAGACTC CTAGCCACAG
1251 CTGGAGCAAC GGACACACTG AAAGCATCCT TTCCGAAAGC CACTCTGTAA
1301 TCGTGATGTC ATCCGTAGAA AACAGTAGGC ACAGCAGCCC AACTGGGGCC
1351 G

0012506 05149

6/25 54

FIGURE 4

1 ACKMLYHLVG GASAW*WTVR AARPSSGGEP MEIYSPDMSE VAAERSSSPS
51 TQLSADPSLD GLPAAEDMPE PQTEDGRTPG LVGLAVPCCA CLEAERLRGC
101 LNSEKICIVP ILACLVSCLL CIAGLKWVFFV DKIFEYDSPT HLDPGGLGQD
151 PIISLATAA SAVWVSSEAY TSPVSRAQSE SEVQVTVQGD KAVVSFEPSA
201 APTPKNRIFA FSFLPSTAPS FPSPTRNPEV RTPKSATQPO TTETNLQTAP
251 KLSTSTSTTG TSHLVKCAEK EKTFCVNGGE CFMVKDLSNP SRYLCKGGGA
301 VPEESADHNR HLHRPPCGRH HVCGGLLQONQ ETAEKAA*PS SAEPSV*TKQ
351 YDEHCQWASP S*PTPRECPC GESIRI*KRH LQ*AYC*ERS RDILFHQSLY
401 FHSPSLHYCH PDS*PQLEQR TH*KHPFRKP LCNRDVIRRK Q*AQQPNWG

00112506 1054400

FIGURE 5A




FIGURE 5B






FIGURE 6



9/25 54

FIGURE 7


Developmental Northern of ARIA
and nARIA in the chick hindbrain
and cerebellum



0912505 051499

10/25 54


FIGURE 8A



00312595-051499

11/25 54

FIGURE 8B



00310506 001400

12/25 54

FIGURE 9A






FIGURE 9B



13/25 54


FIGURE 9C



00315506 051400

14/25 54

FIGURE 10B
ED5 trunk cross-section



ARIA specific probe

FIGURE 10A
ED5 trunk cross-section



nARIA specific probe

004150-9090700

64450" 96521E60

15/25 54

FIGURE 10D
ARIA specific probe



ED7 trunk cross-section

FIGURE 10C
nARIA specific probe



ED7 trunk cross-section

16/25⁵⁴

FIGURE 11A

A. MCF-7




FIGURE 11B

B. LSG






FIGURE 11C

C. TIME COURSE



0516595.051499

FIGURE 12



nARIA

ARIA

18/26 54

FIGURE 13A

ED9 5% ufCEE ACh response





FIGURE 13B

ED9 2%ufCEE GABA response



ED11 **FIGURE 13D**






FIGURE 13C




19/20 54

20/25 54

FIGURE 14B




FIGURE 14A



21/25 54

FIGURE 15




00340504 074499

22/28 S4

FIG. 16

8% non-denaturing



0312596 031499

23/25 54


FIG. 17



09312596-051499


24/25 54

FIG. 18



25/26 54

FIG. 19



no treatment=sympathetic neurons alone

'Pre'=treatment of sympathetic neurons with presynaptic input-conditioned media+various oligos

mmAS=mismatch antisense control

nARIA AS=nARIA specific antisense oligonucleotides

ARIA AS=ARIA specific antisense oligonucleotides

26/54


TABLE P1-1	$\alpha 3$	$\alpha 5$	$\alpha 7$	$\beta 4$
SYMPs ALONE (set to $\equiv 1$) mRNA/SyMp (fg/100 fg std)	1.2 ± 0.2	0.4 $\pm .01$	0.2 $\pm .05$	0.4 ± 0.1
SyMps + INPUT	4.9	6.6	18	1.6
SyMps + TARGET	0.6	6.3	3.0	4.6
SYMPs+ INPUT+ TARGET	2.7	10	23	10
. <i>in vivo</i> DEVELOPMENT	2.8	11	21	12

Anterograde (Input) and Retrograde (Target) co regulation of nAChR expression utilize distinct (~ additive) mechanisms.

nAChR mRNA were assayed from synaptically naive SyNs (E9 chick) *in vitro*. Conditions indicated & presented as fold change relative to E9 SyMps ($\equiv 1$). n= (from top): 49, 51, 17, 31, 6 experiments of each condition. Single cell qPCR following electrophysiology. data corrected for amplification efficiency & actin standard (& Prog.: A2) ^RNase protection assay of E8 vs. E21, corrected for neuron number and actin standard. + heart target data: # kidney target data (see Aim 2 Progress)

00712595-051499

A. TREATMENT with RECOMBINANT CRD-NRG MIMICS the INDUCTION of nAChRs BY INPUT & INPUT-DERIVED CM



B. FUNCTIONAL DELETION of CRD-NRG BLOCKS nAChR INDUCTION by INPUT-CM & ALTERS the NUMBER & PROFILE of SYNAPTIC nAChR CHANNELS






FIG. P1-1: Regulation of postsynaptic nAChRs by CRD-NRG in E9 chick sympathetic neurons.

Input-dependent induction of postsynaptic nAChRs is mimicked by CRD-NRG (A) and inhibited by CRD-NRG AS treatment (B). CRD-NRG is required for nAChR induction by input-derived soluble factors (CM) since postsynaptic nAChR induction by VMN input is strongly inhibited by CRD-NRG AS (B; Middle). Analysis of synaptic currents (SPSCs) at CRD-NRG "deleted" synapses reveals that this NRG isoform is required for the expression of the mature array of high f_r , brief nAChR channel subtypes, normally induced by VMN input (B; far right). Synapses innervated by CRD-NRG AS-treated VMN express long τ , immature nAChRs, akin to those detected prior to synaptogenesis. MM = mismatch (control) oligo

28/54



CONTROL (+/-) CRD-NRG (-/-)
VAT Ab STAINING



30/54




FIG. P2-1

[illegible]

INPUT ONLY






TABLE P2-1: Σ Regulation of nAChR s									
γ (pS)	$(\alpha 3)_2(\beta x)_3$	$(\alpha 3)_1(\alpha 7)_1(\beta x)_3$	$(\alpha 3)_3(\beta x)_2$	$(\alpha 3)_1(\alpha 5)_1(\alpha 7)_1(\beta x)_2$	$(\alpha 3)_2(\alpha 5)_2(\beta x)$	$(\alpha 3)_1(\alpha 5)_1(\alpha 7)_1(\beta x)$	$(\alpha 3)_1(\alpha 5)_2(\alpha 7)_1(\beta x)$	$\alpha 7$	
τ 1 (ms)	13.5 ± 2	23 ± 3	28 ± 4	38 ± 6	50 ± 3	51 ± 3	66 ± 7		
τ 2 (ms)	2.1 ± 5	1.1 ± 0.2	1.7 ± 0.1	1.7 ± 0.1	3.3 ± 0.5	3.3 ± 0.4	2.5 ± 0.8		
	7.6 ± 1 (65%)	7.0 ± 1 (60%)	13 ± 0.9	10.8 ± 0.4 (67%)	-	16.6 ± 3.1 (39%)			
ABUNDANCE									
Early develop.	++++	-	++	-	+	-	-	-	-
Intermediate	+++	+	++	++++	+++	+++	+	+	+
Late develop.	-	++	-	++++	++++	++++	++++	++	++
INDUCED by...									
Input	-	-	-	++	+++	++	+	+	+
Contact with kidney	-	-	-	+	++++	-	-	+++	+++
Contact with heart	++++	++	+	-	-	-	-	-	-
PHARMACOLOGY									
ACh (rel. K_{app})	++++	+++	++++	++	++	+	+	+	+
Cytisine ²	+	-	+	-	+	-	-	ND	ND
n-BgTx sensitivity	+	+	+	+	+	+	+	+	+
α -BgTx sensitivity	-	+	-	-	-	-	-	ND	ND
MLA sensitivity ²	-	-	-	+	-	+	+	+	+
DELETED by AS to:	$\alpha 3$	$\alpha 3, \alpha 7$	$\alpha 3$	$\alpha 3, \alpha 5, \alpha 7$	$\alpha 3, \alpha 5$	$\alpha 3, \alpha 5, \alpha 7$	$\alpha 3, \alpha 5, \alpha 7$	$\alpha 7, ND$	

33/54


You have made it to AIM 1 FIGS AND TABLES

Table A1-1: The profile of nAChR subunit gene expression in the visceral motor & medial habenula nuclei changes during <i>in vivo</i> synaptogenesis.						
	$\alpha 3$	$\alpha 4$	$\alpha 5$	$\alpha 7$	$\beta 2$	$\beta 4$
Visc. Motor						
E18 vs. P0. mouse	↑	↑	-	↑	↑	ND
E9 vs. E18. chick	ND	↑↑	↑	↑	↓	↑
Med. Habenula						
E16 vs. P0. mouse	↑	↑	↑	↑	↑↑	ND
E11 vs. E17 chick	↓	-	↑	↑↑	↑↑	↑↑
qPCR assay of chick tissue extracts: mouse data from "side-by-side" <i>in situ</i> assays (^{FN1} , Methods). ND: not determined: - no change or low signal.						

00312596-054499

34/54

FIG A1-1: The profile of nAChR subunit gene expression in presynaptic VMN and MHN neurons is strongly regulated by interaction with neuronal targets *in vitro*.




nAChR subunit mRNA levels were assayed by qPCR of chick neurons *in vitro* ± synaptic partners.. The levels of subunit mRNA in "synaptically naive" neurons is set to 1.

004150 00000000

35/54

00340596 051409


Sample recordings of
mouse nAChRs




36/54

Fig A1-2 Mapping postsynaptic "hotspots" by VC recording:

WCR and tests at 5 sites of n-n contact reveals post-synaptic hotspot areas of agonist response.



Mapping presynaptic nAChR "hotspots" by fura2-imaging of nicotine-elicited $[Ca^{2+}]$ transients. Nicotine ($1\mu M$) was applied at 25 areas eliciting increased $[Ca]$ at 10 presynaptic hotspots (red filled circles & \square in C). Blue / open circles areas tested, - after Mn quench.



Internal Mn perfusion of postsynaptic n. (A & pseudo color purple) quenches somatic signal (B) and unveils presynaptic fibers (C; & yellow / green) calib: 0.2 fluor units x 20 secs

09312506-051499

37/54


TABLE A1-2	AChE Fibers	$\alpha 3$	$\alpha 4$	$\alpha 5$	$\alpha 7$	$\beta 2$
IPN						
E16	+	-	-	+	-	++
E18/P0	+++	+/-	+	++	+/-	++
P7	+++	++	++	+++	++	+
AMYG						
E16	-	-	-	-	-	-
E18/P0	+ (gc)	+/-	++	+/-	+	+/++
P7	+++	ND	+++	+	+++	++

"Amygdala" refers to 2 major cholinceptive subregions: the basolateral nucleus (BLA), and the Nucleus of the lateral olfactory tract nuclei (NLOT). (gc)= growth cone tipped AChE + fibers. ND= not determined.

00012506-041400

38/54


Fig A1-3: *In vitro* innervation of IPN by MHN alters the profile of nAChR subunits expressed and increases the magnitude of nAChR-mediated currents



00312596 1061490

39/54


Fig A1-5: Nicotine induces robust synaptic facilitation: slice-patch recording from PO mouse IPN (B). Neurons are dye filled for subsequent re-location (A)



00015506 051490 00015506 051490

40/54

Fig A1-4: Cholinergic fibers exit mouse MHN micro-explants (VAT+: red). Contacts with IPN MAP + dendrites are common (green).



00312596 051490

41/54


TABLE A2-1	$\alpha 3$	$\alpha 4$	$\alpha 5$	$\alpha 7$	$\beta 2$	$\beta 4$
VMNs <i>in vivo</i> (mouse) DEV. Δ 's; E16 vs. P0 CRD(-/-) vs. CONT	\uparrow ND	\uparrow $\downarrow\downarrow$	- -	\uparrow \downarrow	\uparrow \downarrow	ND ND
(chick) <i>in vitro</i> Δ with target Δ with CRD NRG	\uparrow $\downarrow?$	$\uparrow\uparrow$ \uparrow	\uparrow no	\uparrow \uparrow	ND ND	$\uparrow\uparrow$ $\uparrow\uparrow$
MHN <i>in vivo</i> DEV. Δ 's CRD(-/-) vs. CONT	\uparrow no Δ	\uparrow $\downarrow?$	\uparrow \downarrow	\uparrow \downarrow	$\uparrow\uparrow$ $\downarrow?$	$\uparrow\uparrow$ ND
<i>in vitro</i> Δ with target Δ with CRD NRG	\uparrow \uparrow	\downarrow \uparrow	\downarrow \downarrow	$\uparrow\uparrow$ $\uparrow\uparrow\uparrow$	$\uparrow\uparrow\uparrow$ $\uparrow\uparrow\uparrow$	\uparrow $\uparrow\uparrow$
IPN <i>in vivo</i> DEV. Δ 's CRD(-/-) vs. CONT	$\uparrow\uparrow$ ND	\uparrow \downarrow	$\uparrow\uparrow$ \downarrow	\downarrow no	\uparrow no Δ	$\uparrow\uparrow$ ND
<i>in vitro</i> Δ with input Δ with CRD NRG	\uparrow \uparrow	\uparrow ND	$\uparrow?$ $\uparrow?$	\downarrow $\downarrow\downarrow$	$\uparrow\uparrow$ ND	$\uparrow\uparrow$ -/? \uparrow
AMYGD <i>in vivo</i> Δ DEV (P0 vs. P7) Δ in CRD(-/-), P0 m. E16 mouse <i>in vitro</i> Δ with input	ND ND $\sim\uparrow$	\uparrow \downarrow $\sim\uparrow$	$\uparrow?$ $\downarrow?$ $\sim\uparrow$	$\uparrow\uparrow\uparrow$ $\downarrow?$ $\uparrow\uparrow$	no Δ no Δ no Δ	ND ND ND

Mouse "in vivo" data refers to preliminary *in situ* analyses. All *in vitro* data refer to qPCR assays. no Δ : no change in subunit levels. ND= not determined ; - or ? : measurement uncertainty due to low "n" or low levels of expression. Also see Fig A2-2;

0031956-054499

42/54

Fig A2-1: Recombinant CRD-NRG alters profile of nAChR subunit genes expressed in chick MHN neurons




nAChR subunit mRNA levels were assayed by qPCR of chick MHN neurons *in vitro*, treated (24 hrs) with rCRD-NRG or mock. The levels of subunit mRNA in mock treated neurons is set to 1.

09712596-091490

43/54

054150 9652150

Fig A2-2 CRD-NRG signaling may be required for expression &/or targeting of presynaptic nAChRs in CNS neurons



(A) Control: presynaptic nAChRs are present at VMN – SyMp synapses, as detected by increased sEPSC frequency (synaptic facilitation) with applied nicotine. (B) Treatment of VMNs with CRD-NRG AS- (48 hrs) blocks nicotine-induced facilitation, although baseline synaptic activity (sEPSC freq. without nicotine) is unaffected. MM = mismatch (control) oligo

Fig A2-3 CRD-NRG enhances axonal targeting of (AdV -tagged) $\alpha 4$ containing nAChRs in MHN neurons


A

B

+ CRD-NRG


C

After Adenovirus mediated gene transfer of $\alpha 4$ - FLAG in MHN, FLAG- nAChRs are seen only on the soma of control neurons., whereas in CRD NRG treated (24 hrs). neurons. FLAG nAChRs are detected in MAP-minus neurites.




After Adenovirus mediated gene transfer of $\alpha 4$ - FLAG in MHN, FLAG- nAChRs are seen only on the soma of control neurons., whereas in CRD NRG treated (24 hrs). neurons. FLAG nAChRs are detected in MAP-minus neurites.

45/54




00312595.051499

46/54




000000-051000

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---




48/54


C



064590-064490



E






49/54

A


FIGURE 2A Wolpowitz et al

P0

CONTROL




CRD-NRG (-/-)



NF

+ α BgTx




AChE



H&E

664150-9652160

FIGURE 2B Wolpowitz et al




09312596-051499


51/54

FIGURE 3(A,B) Wolpowitz et al

A






B



52/54

C

CRD-NRG (-/-) CONTROL



VAT Ab

erbB3
mRNA


VAT +
s100

FIGURE 3(C) Wolpowitz et al

7

00150-9662160

CN5-GANGLION



53/54

54/54

B




FIGURE 4B Wolpowitz et al

09312596 .051499